𝛼SK or Search

ENTITY

Laekna (2105 HK)

36

Analysis

Health Care • China

Laekna is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer, metabolic diseases, and liver fibrosis. Its pipeline includes drug candidates such as LAE002 for breast and prostate cancer, LAE001 for prostate cancer, and LAE102 for obesity. The company was founded in 2016 and is headquartered in Yuyao, China.

more

Refresh

Exchange Announcement • 13 Oct 2026 08:10

Voluntary Announcement Updates On The 24-Week Monotherapy Study Of Lae102 Showed Promising Weight Losses Favorable Changes In Body Composition And Well Tolerated Safety Profile

Exchange Announcement • 18 Sep 2026 22:52

Interim Report 2026

Exchange Announcement • 08 Sep 2026 20:13

Next Day Disclosure Return

Exchange Announcement • 01 Sep 2026 08:10

Voluntary Announcement First Subject Enrolled In The Phase I Clinical Study Of Lae118 (A Novel Pi3k Alpha Pan-Mutant Selective Inhibitor)

Exchange Announcement • 25 Aug 2026 22:47

Interim Results Announcement For Six Months Ended June 30, 2026

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x